Mutations in BC risk genes might be valuable markers for therapy response prediction, which already has been reported for BRCA1- and BRCA2-associated BC, suggesting higher sensitivity to anthracyclines, platinum and potentially other agents (Bayraktar and Gluck 2012; Kriege et al. 2009; Tutt et al. 2010). The gene discussed is BRCA2; the disease is breast cancer.